These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 874815)

  • 21. Antihypertensive activity of captopril (SQ 14,225), an orally active inhibitor of angiotensin converting enzyme in conscious two-kidney perinephritic hypertensive dogs.
    Vollmer RR; Boccagno JA; Steinbacher TE; Horovitz ZP; Murthy VS
    J Pharmacol Exp Ther; 1981 Feb; 216(2):225-31. PubMed ID: 6257882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of L-dopa on peripheral sympathetic nerve function: role of presynaptic dopamine receptors.
    Lokhandwala MF; Buckley JP
    J Pharmacol Exp Ther; 1978 Feb; 204(2):362-71. PubMed ID: 621670
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs.
    Lovinger R; Holland J; Kaplan S; Grumbach M; Boryczka AT; Shackelford R; Salmon J; Reid IA; Ganong WF
    Neuroscience; 1976 Dec; 1(6):443-50. PubMed ID: 11370235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine1 receptor stimulation.
    Montier F; Katchadourian P; Pratz J; Cavero I
    J Cardiovasc Pharmacol; 1989 May; 13(5):739-47. PubMed ID: 2472522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
    Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
    J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
    Johansson P
    Acta Physiol Scand; 1982 Sep; 116(1):37-40. PubMed ID: 7158390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
    Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma epinephrine and control of plasma renin activity: possible extrarenal mechanisms.
    Johnson MD; Fahri ER; Troen BR; Barger AC
    Am J Physiol; 1979 Jun; 236(6):H854-9. PubMed ID: 443450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmatic renin activity in patients treated with L-dopa and inhibitor of dopa decarboxylase (IDC).
    Allain H; Van den Driessche J; Bentue-Ferrer D; Reymann JM; Pape D; Madigand M
    Psychopharmacology (Berl); 1979 Mar; 61(2):197-202. PubMed ID: 108737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man.
    Caldara R; Barbieri C; Piepoli V; Borzio M; Masci E
    Gut; 1985 Oct; 26(10):1014-7. PubMed ID: 4054700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man.
    Worth D; Harvey J; Brown J; Lee M
    Eur J Clin Pharmacol; 1988; 35(2):137-41. PubMed ID: 3056728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase.
    Waterhouse MJ; Chia YC; Lees GJ
    Mol Pharmacol; 1979 Jan; 15(1):108-14. PubMed ID: 423884
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of the renin--aldosterone axis and of prolactin secretion during pregnancy by L-dopa.
    Kaulhausen H; Oney T; Leyendecker G
    Br J Obstet Gynaecol; 1982 Jun; 89(6):483-8. PubMed ID: 7044409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
    Rose S; Jenner P; Marsden CD
    J Pharm Pharmacol; 1993 Aug; 45(8):725-30. PubMed ID: 7901371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the responses of plasma renin activity and aldosterone and cortisol levels to dopaminergic and opiate stimuli in man.
    Lightman SL
    Clin Endocrinol (Oxf); 1981 Jul; 15(1):45-52. PubMed ID: 7030527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):576-81. PubMed ID: 8133901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of phenytoin, ethosuximide and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat.
    Scuvee-Moreau J; Lepot M; Brotchi J; Gerebtzoff MA; Dresse A
    Arch Int Pharmacodyn Ther; 1977 Nov; 230(1):92-9. PubMed ID: 603313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
    Fevang FO; Stoa RF; Thorsen T; Aarskog D
    Acta Paediatr Scand; 1977 Jan; 66(1):81-4. PubMed ID: 831384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.